Immunization, HepB3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
Middle East, North Africa, Afghanistan & Pakistan (excluding high income): Immunization, HepB3 was 83.7% in 2024. ◆ Volatile
Immunization, HepB3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), 1985–2024
Source: World Health Organization (WHO). Measured in % of one-year-old children.
Analysis
In 2024, immunization, hepb3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) stood at 83.7%.
Compared with earlier readings it is up 6.4% over ten years.
Over the whole period, immunization, hepb3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) peaked at 84.6% in 2019 and was at its lowest, 0.0%, in 1985.
Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 27th of 47 groups on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Immunization, HepB3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income), year by year
| Year | % of one-year-old children | Change |
|---|---|---|
| 1985 | 0.0% | — |
| 1986 | 0.0% | — |
| 1987 | 0.0% | — |
| 1988 | 0.0% | — |
| 1989 | 0.0% | — |
| 1990 | 0.0% | — |
| 1991 | 0.0% | — |
| 1992 | 1.0% | — |
| 1993 | 1.6% | +65.0% |
| 1994 | 21.2% | +1188.7% |
| 1995 | 25.4% | +20.0% |
| 1996 | 27.4% | +7.7% |
| 1997 | 31.1% | +13.5% |
| 1998 | 28.0% | -10.0% |
| 1999 | 34.2% | +22.1% |
| 2000 | 37.6% | +10.1% |
| 2001 | 39.5% | +4.9% |
| 2002 | 40.4% | +2.3% |
| 2003 | 65.1% | +61.3% |
| 2004 | 68.9% | +5.8% |
| 2005 | 72.8% | +5.6% |
| 2006 | 70.6% | -3.0% |
| 2007 | 73.3% | +3.9% |
| 2008 | 73.9% | +0.7% |
| 2009 | 74.1% | +0.3% |
| 2010 | 74.1% | +0.0% |
| 2011 | 77.6% | +4.7% |
| 2012 | 76.0% | -2.2% |
| 2013 | 78.4% | +3.2% |
| 2014 | 78.7% | +0.3% |
| 2015 | 79.3% | +0.8% |
| 2016 | 81.3% | +2.5% |
| 2017 | 81.5% | +0.2% |
| 2018 | 83.4% | +2.3% |
| 2019 | 84.6% | +1.4% |
| 2020 | 80.7% | -4.5% |
| 2021 | 81.3% | +0.7% |
| 2022 | 83.4% | +2.6% |
| 2023 | 83.7% | +0.3% |
| 2024 | 83.7% | -0.0% |
Biggest year-on-year movements
Years where Immunization, HepB3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 1994 | +1188.7% | 1.6% | 21.2% |
| 1993 | +65.0% | 1.0% | 1.6% |
| 2003 | +61.3% | 40.4% | 65.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1980s | 0.0% | 0.0% | 0.0% | 5 |
| 1990s | 17.0% | 0.0% | 34.2% | 10 |
| 2000s | 61.6% | 37.6% | 74.1% | 10 |
| 2010s | 79.5% | 74.1% | 84.6% | 10 |
| 2020s | 82.6% | 80.7% | 83.7% | 5 |
Countries ranked near Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
- 26 Albania 97.0% compare
- 26 Andorra 97.0% compare
- 26 Bangladesh 97.0% compare
- 26 Belgium 97.0% compare
- 26 Egypt 97.0% compare
- 26 South Korea 97.0% compare
- 26 Malta 97.0% compare
- 26 Nauru 97.0% compare
- 26 Nepal 97.0% compare
- 26 Russia 97.0% compare
- 26 Saudi Arabia 97.0% compare
- 26 Sri Lanka 97.0% compare
- 26 Saint Kitts and Nevis 97.0% compare
- 26 Tajikistan 97.0% compare
- 26 Tunisia 97.0% compare
- 26 Vietnam 97.0% compare
More health data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income)
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, annual growth rate 3.11 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0305 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 3.21 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0351 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 1.51 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0341 units per person (2025)
- Population ages 30-34, female, annual growth rate 0.4849 % change on previous year (2025)
All data for Middle East, North Africa, Afghanistan & Pakistan (excluding high income) →
Frequently asked questions
- What is immunization, hepb3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Immunization, hepb3 in Middle East, North Africa, Afghanistan & Pakistan (excluding high income) was 83.7% in 2024, according to World Health Organization (WHO).
- What is the highest immunization, hepb3 recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The highest recorded value was 84.6% in 2019.
- What is the lowest immunization, hepb3 recorded in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- The lowest recorded value was 0.0% in 1985.
- How does Middle East, North Africa, Afghanistan & Pakistan (excluding high income) rank for immunization, hepb3?
- Middle East, North Africa, Afghanistan & Pakistan (excluding high income) ranks 27th out of 47 groups with data for 2024.
- Is immunization, hepb3 rising or falling in Middle East, North Africa, Afghanistan & Pakistan (excluding high income)?
- Over the last ten years it is up 6.4%. The long-run trend across the full record is volatile.
- Where does this Middle East, North Africa, Afghanistan & Pakistan (excluding high income) data come from?
- The figures come from World Health Organization (WHO), published as part of Immunization, HepB3 (% of one-year-old children). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 40 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.